KalVista Pharmaceuticals (KALV) Accumulated Expenses (2014 - 2025)

KalVista Pharmaceuticals (KALV) has 12 years of Accumulated Expenses data on file, last reported at $19.0 million in Q3 2025.

• For the quarter ending Q3 2025, Accumulated Expenses rose 83.21% year-over-year to $19.0 million; the trailing twelve-month figure through Jul 2025 stood at $19.0 million (up 83.21% YoY), and the FY2025 full-year result was $27.3 million, up 120.25% from the prior year.
• Accumulated Expenses fell to $19.0 million in Q3 2025, from $27.3 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $27.3 million in Q2 2025 to a low of $1.6 million in Q3 2021.
• A 5-year average of $8.1 million and a median of $5.8 million in 2022 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses sank 74.41% in 2021 and jumped 314.03% in 2024, its largest moves.
• Tracing KALV's Accumulated Expenses over 5 years: stood at $2.4 million in 2021, then soared by 187.8% to $6.9 million in 2022, then jumped by 69.42% to $11.7 million in 2023, then declined by 28.79% to $8.3 million in 2024, then surged by 127.58% to $19.0 million in 2025.
• Business Quant data shows KALV's Accumulated Expenses at $19.0 million in Q3 2025, $27.3 million in Q2 2025, and $8.3 million in Q4 2024.